pep005 and bryostatin-1

pep005 has been researched along with bryostatin-1* in 2 studies

Other Studies

2 other study(ies) available for pep005 and bryostatin-1

ArticleYear
Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages.
    Journal of virology, 2022, 02-23, Volume: 96, Issue:4

    While combination antiretroviral therapy maintains undetectable viremia in people living with HIV (PLWH), a lifelong treatment is necessary to prevent viremic rebound after therapy cessation. This rebound seemed mainly caused by long-lived HIV-1 latently infected cells reverting to a viral productive status. Reversing latency and elimination of these cells by the so-called shock-and-kill strategy is one of the main investigated leads to achieve an HIV-1 cure. Small molecules referred to as latency reversal agents (LRAs) proved to efficiently reactivate latent CD4

    Topics: Anti-HIV Agents; Bryostatins; CD4 Antigens; CD4-Positive T-Lymphocytes; Depsipeptides; Diterpenes; HIV Core Protein p24; HIV-1; Humans; Macrophages; Receptors, CCR5; SAM Domain and HD Domain-Containing Protein 1; Virus Activation; Virus Latency; Virus Replication

2022
Rebound increases in chemokines by CXCR2 antagonist in breast cancer can be prevented by PKCδ and PKCε activators.
    Cytokine, 2021, Volume: 142

    Activation of CXCR2 by chemokines such as CXCL1 and CXCL2 increases aggressiveness of breast cancer, inducing chemoresistance, hence CXCR2 antagonists are in clinical trials. We previously reported that inhibition of CXCR2 increases MIP-2 (CXCL2), which may inhibit anti-tumoral effects of CXCR2 antagonists. This seems to be due to inhibition of protein kinase C (PKC) by CXCR2 antagonist since specific inhibitor of PKC also enhances MIP-2 secretion. We here examined whether CXCR2 inhibitor also increases KC (CXCL1) secretion, ligand for CXCR2 involved in metastasis and PKC activators can prevent increases in chemokine secretion. We used SB 225002, which is a specific CXCR2 antagonist. The effects of PKC activators that have documented anti-tumoral effects and activates multiple isozymes of PKC such as Ingenol-3-angelate (I3A) and bryostatin-1 were examined here. In addition, FR236924, PKCε selective and 7α-acetoxy-6β-benzoyloxy-12-O-benzoylroyleanone (Roy-Bz), PKCδ selective activators were also tested. The effects of activators were determined using brain metastatic (4TBM) and heart metastatic (4THM) subset of 4T1 breast carcinoma cells because these aggressive carcinoma cells with cancer stem cell features secrete high levels of KC and MIP-2. Inhibition of CXCR-2 activity increased KC (CXCL1) secretion. PKC activators prevented SB225002-induced increases in KC and MIP-2 secretion. Different activators/modulators induce differential changes in basal and SB225002-induced chemokine secretion as well as cell proliferation and the activators that act on PKCδ and/or PKCε such as bryostatin 1, FR236924 and Roy-Bz are the most effective. These activators alone also decrease cell proliferation or chemokine secretion or both. Given the role of KC and MIP-2 in drug resistance including chemotherapeutics, activators of PKCε and PKCδ may prevent emerging of resistance to CXCR2 inhibitors as well as other chemotherapeutics.

    Topics: Alkanes; Animals; Bryostatins; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL2; Chemokines; Cyclopropanes; Diterpenes; Enzyme Activators; Extracellular Signal-Regulated MAP Kinases; Female; Indoles; Mammary Neoplasms, Animal; Mice, Inbred BALB C; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Protein Kinase C-delta; Protein Kinase C-epsilon; Receptors, Interleukin-8B

2021